MediciNova terminated its Standby Equity Purchase Agreement with Yorkville II PN, Ltd. effective September 8, 2026. The company previously sold 175,000 shares for $0.2 million under the agreement and had no outstanding obligations or fees due upon termination. MediciNova is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases.
